Astatine-211 based radionuclide therapy: Current clinical trial landscape

Per Albertsson; Tom Bäck; Karin Bergmark; Andreas Hallqvist; Mia Johansson; Emma Aneheim; Sture Lindegren; Chiara Timperanza; Knut Smerud; Stig Palm

doi:10.3389/fmed.2022.1076210

Astatine-211 based radionuclide therapy: Current clinical trial landscape

Front Med (Lausanne). 2023 Jan 6:9:1076210. doi: 10.3389/fmed.2022.1076210. eCollection 2022.

Authors

Per Albertsson^{1

2}, Tom Bäck³, Karin Bergmark^{1

2}, Andreas Hallqvist^{1

2}, Mia Johansson^{1

2}, Emma Aneheim^{1

3}, Sture Lindegren³, Chiara Timperanza³, Knut Smerud⁴, Stig Palm³

Affiliations

¹ Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.
² Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
³ Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
⁴ Smerud Medical Research International AS, Oslo, Norway.

Abstract

Astatine-211 (²¹¹At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of the completed clinical trials, further describe ongoing trials, and discuss future prospects.

Keywords: alpha particle; astatine-211; clinical trial; human; radionuclide; targeted alpha therapy.

Publication types

Review

Grants and funding

This work was supported by the Swedish Research Council (2020-02204), the Swedish Cancer Society (190523Pj, 190523Fk), the King Gustav V Jubilee Clinic Research Foundation, the Swedish Radiation Protection Authority, the Gösta Miltons Foundation, and grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALFGBG-966276, ALFGBG-873621).